The missing millions: a threat to the elimination of leprosy
Autor: | Paul Saunderson, William Cairns Stewart Smith, Wim H. van Brakel, Jan Hendrik Richardus, Tom Gillis |
---|---|
Přispěvatelé: | Public Health |
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
Lepromatous leprosy
medicine.medical_specialty Pathology lcsh:Arctic medicine. Tropical medicine biology business.industry lcsh:RC955-962 Public health lcsh:Public aspects of medicine Public Health Environmental and Occupational Health Prevalence lcsh:RA1-1270 Disease Dapsone medicine.disease biology.organism_classification Viewpoints Infectious Diseases Family medicine medicine Global health Leprosy business Mycobacterium leprae medicine.drug |
Zdroj: | PLoS Neglected Tropical Diseases, Vol 9, Iss 4, p e0003658 (2015) PLoS Neglected Tropical Diseases (print), 9(4). Public Library of Science PLoS Neglected Tropical Diseases |
ISSN: | 1935-2735 1935-2727 |
Popis: | Leprosy is a slow, chronic disease with a long incubation period caused by Mycobacterium leprae. The clinical presentation varies across a wide spectrum from tuberculoid to lepromatous leprosy. The condition is characterized by skin lesions and damage to peripheral nerves leading to physical disability and social problems. The past 50–60 years have witnessed remarkable progress in the fight against leprosy. The introduction of dapsone therapy in the late 1940s was the first effective treatment for leprosy, and this was followed by the move to short course multidrug therapy (MDT) in 1981. The World Health Assembly Resolution in 1991 [1] to “eliminate leprosy as a public health problem” by the year 2000 galvanised extraordinary international support resulting in the fall in the point prevalence of patients registered for treatment of leprosy by over 90% to less than 1 in 10,000 at the global level. The effort was led by the World Health Organization (WHO) and supported by national governments and their health service staff, the Nippon Foundation, Novartis, the International Federation of Anti-Leprosy Organizations (ILEP), local non-governmental organizations (NGOs), and by people affected by leprosy. Since 2000, the focus has moved from prevalence of leprosy to incidence as measured by reported new case detection to sustain the achievements and to reduce the burden of disease, particularly on reduction and prevention of disability associated with leprosy and rehabilitation of those facing the long-term consequences of the disease [2]. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |